We are live on
!
Find out more
Calamos Advisors Portfolio holdings
AUM
$28.2B
1-Year Est. Return
21.78%
This Fund
S&P 500
This Quarter
Est. Return
+17.1%
1 Year Est. Return
+21.78%
3 Year Est. Return
+69.57%
5 Year Est. Return
+92%
10 Year Est. Return
+282.63%
AUM
$14.1B
AUM Growth
+$1.4B
(+11%)
Cap. Flow
-$4.28B
Cap. Flow
% of AUM
-30.25%
Top 10 Holdings %
Top 10 Hldgs %
20.4%
Holding
803
New
108
Increased
91
Reduced
295
Closed
98
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BSX.PRA
Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A
BSX.PRA
|
+$61M |
| 2 |
RTX Corp
RTX
|
+$38.2M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$15.5M |
| 4 |
Delta Air Lines
DAL
|
+$14.5M |
| 5 |
SWT
Stanley Black & Decker, Inc.
SWT
|
+$13.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$578M |
| 2 |
AGN
Allergan plc
AGN
|
+$67M |
| 3 |
BDXA
Becton, Dickinson and Company Depositary Shares, each Representing a 1/20th Interest in a Share of 6
BDXA
|
+$51.1M |
| 4 |
Alibaba
BABA
|
+$46.8M |
| 5 |
lululemon athletica
LULU
|
+$42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.91% |
| 2 | Healthcare | 8.15% |
| 3 | Consumer Discretionary | 7.49% |
| 4 | Financials | 7.2% |
| 5 | Communication Services | 5.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
ACM Research
ACMR
$4.98B
| $2M | 0.01% |
95,991
-139,044
| -59% | -$2.28M |
|
|
IMMU
427
DELISTED
Immunomedics Inc
IMMU
| $1.93M | 0.01% |
+54,384
| New | +$1.59M |
|
428
PVH
PVH
$4.01B
| $1.9M | 0.01% |
39,519
-2,529
| -6% | -$118K |
|
429
LoveSac
LOVE
$248M
| $1.87M | 0.01% |
+71,271
| New | +$1.08M |
|
430
BILL Holdings
BILL
$4.62B
| $1.86M | 0.01% |
+20,587
| New | +$1.33M |
|
431
Purple Innovation
PRPL
$35.7M
| $1.85M | 0.01% |
+4,115
| New | +$1.3M |
|
432
Phreesia
PHR
$671M
| $1.77M | 0.01% |
62,517
-35,859
| -36% | -$934K |
|
|
NBIS
433
Nebius Group N.V.
NBIS
$43.1B
| $1.75M | 0.01% |
35,000
+10,535
| +43% | +$422K |
|
434
Akamai
AKAM
$16.3B
| $1.73M | 0.01% |
16,181
+7,906
| +96% | +$795K |
|
435
Alnylam Pharmaceuticals
ALNY
$38.5B
| $1.73M | 0.01% |
+11,660
| New | +$1.57M |
|
|
CALY
436
Callaway Golf Company
CALY
$3.28B
| $1.71M | 0.01% |
+97,649
| New | +$1.36M |
|
437
Silicon Motion
SIMO
$7.51B
| $1.71M | 0.01% |
+35,019
| New | +$1.55M |
|
438
Etsy
ETSY
$8.21B
| $1.7M | 0.01% |
+16,009
| New | +$1.18M |
|
439
MongoDB
MDB
$25B
| $1.67M | 0.01% |
+7,385
| New | +$1.37M |
|
440
JD.com
JD
$42.9B
| $1.66M | 0.01% |
27,597
-7,503
| -21% | -$380K |
|
441
Energy Transfer Partners
ET
$69.5B
| $1.64M | 0.01% |
229,900
| – | – |
|
442
Acadia Pharmaceuticals
ACAD
$4.45B
| $1.63M | 0.01% |
33,534
-39,254
| -54% | -$1.88M |
|
443
Molina Healthcare
MOH
$10.5B
| $1.61M | 0.01% |
+9,069
| New | +$1.54M |
|
444
Five Below
FIVE
$11.5B
| $1.54M | 0.01% |
+14,395
| New | +$1.35M |
|
445
Sony
SONY
$133B
| $1.51M | 0.01% |
109,500
-18,500
| -14% | -$240K |
|
|
AMED
446
DELISTED
Amedisys
AMED
| $1.45M | 0.01% |
7,307
-27,972
| -79% | -$5.22M |
|
447
SelectQuote
SLQT
$132M
| $1.45M | 0.01% |
+57,271
| New | +$1.54M |
|
448
Advanced Energy
AEIS
$10.9B
| $1.45M | 0.01% |
21,331
-59,922
| -74% | -$3.57M |
|
449
Century Communities
CCS
$2.05B
| $1.42M | 0.01% |
+46,392
| New | +$1.11M |
|
450
Wabtec
WAB
$51.7B
| $1.41M | 0.01% |
24,520
-1,477
| -6% | -$83.6K |
|
Similar funds
PCH
N
TWC
FDCDDQ
NA
Calamos Advisors's Q2 2020 Portfolio in Review
As of Q2 2020, Calamos Advisors held 803 positions worth $14.1B, up 11% from $12.7B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Calamos Advisors withdrew a net $4.28B in Q2 2020, closing 98 positions and reducing 295 holdings. Its most notable exit was Allergan plc, an estimated $67M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Calamos Advisors opened a new position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A worth $59.7M.
- Calamos Advisors's largest Q2 2020 buy was Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A: 569,916 shares worth $59.7M.
- Calamos Advisors added most to RTX Corp in Q2 2020, an estimated $38.2M increase.
- Calamos Advisors's biggest Q2 2020 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $578M.
- Calamos Advisors fully exited Allergan plc in Q2 2020, selling an estimated $67M.
- Calamos Advisors's ten largest holdings make up 20% of its $14.1B portfolio in Q2 2020.
- Calamos Advisors opened 108 new positions and closed 98 in Q2 2020.
- Calamos Advisors's portfolio value rose 11% quarter-over-quarter to $14.1B.
Based on Calamos Advisors's 13F filing for Q2 2020, filed 27 Jul 2020.